Bone Biologics filed a patent application with the U.S. Patent and Trademark Office for its NELL-1 protein, according to a June 27 news release.
The patent applies to rhNELL-1 polypeptide and its use for treating bone conditions. The protein is used for spinal fusions.
If approved, the patent will support Bone Biologics’ intellectual property portfolio and plans to advance clinical development.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.